文献速递胸部肿瘤

支气管基因组分类器用于肺癌诊断评估的成本效益

Cost-Effectiveness of a Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer.
PubMed 文献 · J Thorac Oncol · 2017-05-11

本研究采用决策分析马尔可夫模型,基于两项研究(Airway Epithelial Gene Expression in the Diagnosis of Lung Cancer-1 和 -2)的检测性能,比较支气管镜检查联合基因组分类器与单纯支气管镜检查在中危肺癌患者诊断评估中的成本效益。结果显示,使用基因组分类器在1个月和2年时分别减少28%和18%的侵入性操作,总成本与质量调整生命年(QALY)增益相近(分别为27,221美元 vs 27,183美元和1.512 vs 1.509),增量成本效益比为每QALY 15,052美元。作者认为该策略在中危肺癌诊断评估中具有高价值。

要点

  • 在中危肺癌患者中,支气管镜联合基因组分类器较单纯支气管镜减少侵入性操作。
  • 1个月和2年侵入性操作分别减少28%和18%。
  • 增量成本效益比为每QALY 15,052美元,总成本与QALY增益相近。

核心结论

  • 作者分析提示,使用基因组分类器与侵入性操作的显著减少相关,且成本大致相当,因此在中危肺癌患者的诊断评估中是一种高价值策略。

研究设计与样本

  • 决策分析马尔可夫模型,使用Airway Epithelial Gene Expression in the Diagnosis of Lung Cancer-1和-2研究的检测性能,比较支气管镜联合基因组分类器与单纯支气管镜两种策略。
  • 非侵入性和侵入性随访的诊断准确性及相关不良事件率来自已发表文献,操作成本基于索赔数据和2016年住院与门诊报销金额。
  • 模型预测各策略的侵入性随访操作数量、2年成本和质量调整生命年(QALY),并计算按每年3%贴现的增量成本效益比。

主要发现

  • 使用基因组分类器在1个月时减少28%的侵入性操作,在2年时减少18%。
  • 使用分类器的总成本为27,221美元,单纯支气管镜为27,183美元。
  • 使用分类器的QALY为1.512,单纯支气管镜为1.509。
  • 增量成本效益比为每QALY 15,052美元。

临床怎么用

  • 原文结论未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The use of a bronchial genomic classifier has been shown to improve the diagnostic accuracy of bronchoscopy for suspected lung cancer by identifying patients who may be more suitable for radiographic surveillance as opposed to invasive procedures. Our objective was to assess the cost-effectiveness of bronchoscopy plus a genomic classifier versus bronchoscopy alone in the diagnostic work-up of patients at intermediate risk for lung cancer. METHODS: A decision-analytic Markov model was developed to project the costs and effects of two competing strategies by using test performance from the Airway Epithelial Gene Expression in the Diagnosis of Lung Cancer-1 and Airway Epithelial Gene Expression in the Diagnosis of Lung Cancer-2 studies. The diagnostic accuracy of noninvasive and invasive follow-up, as well as associated adverse event rates, were derived from published literature. Procedure costs were based on claims data and 2016 inpatient and outpatient reimbursement amounts. The model projected the number of invasive follow-up procedures, 2-year costs and quality-adjusted life-years (QALYs) by strategy, and resulting incremental cost-effectiveness ratio discounted at 3% per annum. RESULTS: Use of the genomic classifier reduced invasive procedures by 28% at 1 month and 18% at 2 years, respectively. Total costs and QALY gain were similar with classifier use ($27,221 versus $27,183 and 1.512 versus 1.509, respectively), resulting in an incremental cost-effectiveness ratio of $15,052 per QALY. CONCLUSIONS: Our analysis suggests that the use of a genomic classifier is associated with meaningful reductions in invasive procedures at about equal costs and is therefore a high-value strategy in the diagnostic work-up of patients at intermediate risk of lung cancer.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Feller-Kopman D, Liu S, Geisler BP, et al. Cost-Effectiveness of a Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer. J Thorac Oncol. 2017. PMID: 28502850. doi:10.1016/j.jtho.2017.04.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。